Corvus Pharmaceuticals reported early clinical data showing robust activity for oral ITK inhibitor soquelitinib in atopic dermatitis, prompting a sharp market rally. The company said the latest cohort demonstrated deepening responses over eight weeks, including activity in patients previously treated with systemic therapies. Soquelitinib targets IL‑2‑inducible T‑cell kinase (ITK), a mechanism being explored for inflammatory and immune disease indications. Corvus presented cohort data from an ongoing randomized, placebo‑controlled phase I study; management will move the program into mid‑stage testing based on these results. Investors interpreted the readout as evidence the molecule could compete with injectable biologics in efficacy and convenience.